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Nonresponsiveness against hepatitis B vaccination has been described in 4–10% of immunized subjects. We have explored the specific
cell response to hepatitis B surface antigen by analyzing: PBMC proliferation, cytokine production (Th1, Th2 profiles, and TGF-h), and
activation molecules on Th cells. A poor proliferative response was demonstrated in nonresponders (P < 0.05). T cells from responders
produced all tested cytokines (P < 0.01), in contrast with nonresponders subjects (P < 0.05). Expression of CD69 and CD25 was diminished
in T cells from nonresponders (P < 0.01). A reduced expression of CD40L was also detected in T cells from nonresponders (P < 0.01). An
elevated correlation coefficient was observed between CD40L on CD4+ cells and antibody production. These results suggest an overall
inability of T cells to be activated which could be consistent with potential differences in antigen presentation. In conclusion, our results
suggest that an altered Th response may be a consequence of inappropriate early activation events.
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According to the World Health Organization, one-third
of the world’s population has been estimated to be infected
with hepatitis B virus (HBV) of whom more than 350
million are chronic carriers (Chisari, 2000). Vaccination
with the surface antigen of HBV (HBsAg) is considered as
the main strategy for effective control of the infection and
viral transmission (Mahoney, 1999). The commercially
available hepatitis B vaccines used during the past 15 years
have mainly consisted of the major viral envelope protein
(S protein) in particulate form. These vaccines, whether
derived from plasma or produced by recombinant DNA
technology, demonstrate excellent immunogenicity and
protective efficacy (Andre, 1989). However, approximately0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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specific antibodies and remain at risk for hepatitis B
infection (Coates et al., 2001; Szmuness et al., 1980).
These individuals are unable to develop detectable (z1
mIU ml1) or protective (z10 mIU ml1) anti-HBs titers
(Leroux-Roels et al., 1997).
Although genes within the major histocompatibility
complex (MHC) are linked to HBsAg response and nonre-
sponse (Desombere et al., 2000; Kruskall et al., 1992), the
molecular and cellular bases for HBsAg nonresponse are
unknown. Lack of response to HBsAg has been also
attributed to mechanisms including defect in the generation
of primary HBsAg-specific T cells (Avanzini et al., 2001;
Chedid et al., 1997), or B cell repertoires (Shokrgozar and
Shokri, 2001), destruction of HBsAg specific B-cells by
antigen-specific cytotoxic T cells (Barnaba et al., 1990),
immunologic tolerance (del Canho et al., 1994; Milich et
al., 1990), and inadequate Th1 and Th2 cytokine production
to recombinant hepatitis B vaccine (Jafarzadeh and Shokri,
2003; Kardar et al., 2002). Any of which are closely related
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mounting an appropriate immune response depends on the
strict regulation of lymphocyte activation.
To this end, lymphocytes require two independent
signals to become fully activated. The first, an antigen-
specific signal is sent via the unique antigen receptor: T
cell receptor (TCR) on T cells or surface Ig on B cells. The
second signal termed costimulation, is independent of the
antigen receptor and is critical to allow full activation,
sustain cell proliferation, prevent anergy or apoptosis,
induce differentiation to effector and memory status, and
allow cell–cell cooperation (Frauwirth and Thompson,
2002). The best-defined costimulatory signals are mediated
by the B7–CD28 pathway and the CD40–CD40 ligand
(CD40L) interaction (Grewal and Flavell, 1998).
CD40 is constitutively expressed on APCs, and CD40L
is induced on T cells upon antigen recognition. The inter-
action between CD40L and CD40 act in a bidirectional
fashion, mediating both cellular and humoral immune re-
sponse, enhancing T cell response (Grewal and Flavell,
1996). Although the mechanism of this effect is unclear, it
is currently believed that CD40–CD40L interaction serve to
upregulate the expression of B7 on APCs and to induce the
production of cytokines such as IL-12, which promotes T
cell differentiation (Shu et al., 1995). In B cells, cross-
linking CD40 drives differentiation, proliferation, and iso-Fig. 1. Induction of the activation markers CD69 and CD25 in response to HBsA
and naive subjects. Panel a shows the differences (with and without stimulation)
expressed as mean values of percentage of expression and represented in confidenc
(MFI) of CD69-positive cells. Panel c shows the differences in increase of CD25 in
of percentage of expression and represented in confidence intervals. Panel d repres
cells (P < 0.01).type switching while preventing B cell apoptosis (Ochs
et al., 1994).
We hypothesized that a dysfunctional activation of
costimulatory and early activation signals could be in part
responsible for a poor or absent response to HBV vaccina-
tion. Therefore, we conducted an in vitro study to investi-
gate the induction of CD40L and the early activation
markers CD69 and CD25, along with Th1/Th2 cytokine
profiles in response to purified recombinant HBsAg, using
peripheral blood mononuclear cells (PBMC) from respond-
ers and nonresponders to hepatitis B vaccine. To this
purpose, PBMC from immunized (responders and nonres-
ponders) and naive subjects were stimulated with recombi-
nant HBsAg during different incubation times, analyzed for
cell proliferation and expression of surface molecules and
intracellular cytokines by flow cytometry.
We observed that PBMC from nonresponders to recom-
binant hepatitis B vaccine show a deficient proliferative
response against purified HBsAg. Furthermore, CD4+ cells
show a diminished expression of CD25, CD69, and CD40L
receptors (P < 0.01) and low Th1, Th2, and TGF-h
cytokines profiles, upon specific HBsAg stimulation (P <
0.05). These results suggest an inappropriate early activa-
tion signal in T helper cells. CD40L induction was corre-
lated with specific antibody titers. Thus, an impaired early
activation signal of Th cells could explain both a deficientg in a group of anti-hepatitis B immunized (responders and nonresponders)
in increase of CD69 in CD3+ and CD4+ cells from the different groups,
e intervals. Panel b represents the differences in mean fluorescence intensity
CD3+ and CD4+ cells from the different groups, expressed as mean values
ents the differences in mean fluorescence intensity (MFI) of CD25-positive
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antibodies following HBV vaccination.Results
PBMC from nonresponders to hepatitis B do not proliferate
in the presence of recombinant HBsAg
A diminished or absent proliferative response to HBsAg,
has been shown in PBMC and T cell lines from non-
responders to hepatitis B (Chedid et al., 1997; Larsen et al.,
2000). In this study, we have observed, as previously
reported, a poor proliferative response to HBsAg in immu-
nized nonresponder subjects (SI: 0.38 F 0.18) when
compared with immunized responders (SI: 8.08 F 3.62)
(P < 0.05). A positive correlation was observed between
the SI and antibody titers (0.01 F 0.01 vs. 754 F 258 mU/
ml) (r = 0.64, P < 0.01). The non-proliferative response to
HBsAg is a specific feature of these individuals because
stimulation with PWM (a mitogenic agent) induced anFig. 2. CD40L expression and induction upon specific stimulation with HBsAg in
differences (with and without stimulation) of expression (percentages in mean valu
the differences in mean fluorescence intensity (MFI) of CD40L-positive cells. P
expression on CD4+ cells. Graphics 1 and 2 show CD40L expression on unstimu
Graphic 3 is the basal level of surface CD40L in unstimulated cells from responder
cells from responder individuals.adequate proliferative index (SI: 37.83 F 11.94), which
is comparable to that of responders (SI: 59.19 F 40.22) and
naive subjects (SI: 42.76 F 16.47).
T cells from nonresponders individuals express diminished
CD40L, CD25, and CD69 molecules against HBsAg
T cell activation is the central event in the evolution
of antigen-specific cellular and most humoral immune
responses (Frauwirth and Thompson, 2002). One possi-
bility to explain the absence of antigen-specific prolif-
eration in nonresponders to hepatitis B vaccine could be
a defect in early activation signals generated on T cells
because of inappropriate costimulatory signals. To test
this hypothesis, we measured the surface expression of
CD40L, CD25, and CD69 on CD3/CD4-positive cells
from naive and immunized individuals by stimulating
PBMC with HBsAg, as previously described. To ana-
lyze the expression of these markers at the cell level,
an area was drawn on the HBsAg-stimulated lympho-
cytes population using the appropriate fluorochrome-immunized and naive subjects. Panel a represents confidence intervals of the
es) of CD40L, both in CD3+ and CD4+ cells P < 0.01. Panel b represents
anel c is a representative dot plot corresponding to CD40L percentage of
lated and HBsAg-treated cells, respectively, from nonresponder individuals.
subjects, meanwhile graphic 4 shows HBsAg-induced CD40L expression in
Fig. 3. Intracellular cytokine profiles in response to HBsAg stimulation in
cells from immunized and naive subjects. Panel a represents the differences
of cytokine expression (IL-2, IFN-g, IL-4, and IL-13) between unstimulated
and stimulated CD4+ cells, expressed as percentages in mean values,
analyzed in the three groups of individuals. Panel b shows the differences of
TGF-h induction before and after HBsAg-stimulation in CD8+ cells from
studied groups. Panel c shows representative dot plots of intracellular
cytokine expression in CD4+ and CD8+ T cells from responder and
nonresponder subjects, P < 0.01.
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CD69 expression is one of the earliest activation
signals observed in stimulated lymphocytes (Testi et al.,
1988) and its expression has been associated with pro-
liferative cell response (Mardiney et al., 1996). As a
result, we studied the kinetics of CD69 expression against
HBsAg on T cells from naive and hepatitis B-immunized
subjects. A diminished percentage of CD69-positive cells
was observed in nonresponder individuals as compared
with responders (CD3: 0.9 F 0.8 vs. 7.93 F 2.6 CI and
CD4: 11.47 F 3.7 vs. 19.2 F 4.2 CI) (P < 0.01) (Fig.
1a). This result is reinforced by the fact that a diminished
mean fluorescence intensity (MFI) was observed as well
in CD69-positive cells (CD3: 11.5 F 3.2 vs. 47.8 F 7.7
CI and CD4: 13 F3.8 vs. 52.6 F 10 CI) (P < 0.01) (Fig.
1b). To analyze the effect of this result, CD69 expression
was compared with proliferation and, a positive correla-
tion was established between theses two parameters (r =
0.51, P < 0.01); thus, absence of specific proliferation in
nonresponders to hepatitis B vaccine may be secondary
to defects in early cell activation.
CD25 is generally expressed on activated T cells and it
is believed that cells that strongly express the high-affinity
IL-2 receptor (CD25) participate as immunoregulatory T
cells (Baecher-Allan et al., 2001) and are the most likely
candidates to immediate precursors of effector cells
(McNally et al., 1999). In this study, we have observed
that following stimulation with HBsAg, T cells (CD3+/
CD4+) from nonresponder subjects were unable to increase
the percentage of expression of CD25 above those ob-
served in naive individuals (CD3: 2.65 F 1.6 vs. 10.6 F
3.7 CI and CD4: 14.9 F 5.7 vs. 29.8 F 6.6 CI) (P < 0.01).
(Fig. 1c). Fig 1d proves a diminished MFI on CD25-
positive cells from CD3+ and CD4+ cell populations
(CD3: 13 F 9.4 vs. 54.2 F 11.9 CI and CD4: 32 F 7.5
vs. 61.3 F 9.1 CI) (P < 0.01).
Two additional possible causes that could explain the
lack of response in immunized subjects to the hepatitis B
vaccine include: an inadequate cytokine environment or
defects on the CD40–CD40L interaction. The first possi-
bility, as previously shown (Kardar et al., 2002; Larsen et
al., 2000), was confirmed in our study and it is described
bellow. An interesting result was observed when the
second possible cause was explored. A remarkable dimin-
ished expression of CD40L was detected on T cells from
nonresponder subjects, when cells were stimulated with
HBsAg, as compared to naive and good responders (CD3:
0.6 F 0.2 vs. 2.9 F 0.7 CI and CD4: 4.1 F 2.4 vs. 19.4 F
2.7 CI) (P < 0.01) (Figs. 2a and c). Fig. 2b proves a
diminished MFI on CD40L-positive cells from CD3+ and
CD4+ cell populations (CD3: 5.5 F 4.7 vs. 48.6 F 6.6 CI
and CD4: 20 F 10 vs. 53.8 F 8.8 CI) (P < 0.01). An
elevated correlation coefficient was observed between
CD40L expression in CD4+ cells and antibody production
(r = 0.7, P < 0.01).Profiles of cytokines in T cells from naive and immunized
subjects in response to recombinant HBsAg
Cytokine production constitute one of the most impor-
tant signals to evaluate the outcome of the immune
response. There are several reports about an inadequate
cytokine environment, particularly regarding the Th1 pro-
file of cytokines, in nonresponders to hepatitis B vaccine
(Chedid et al., 1997). To analyze the pattern of cytokine
production in T cells from naive and immunized subjects
(responders and nonresponders), we measured intracellular
synthesis of the following cytokines: IL-2, IFN-g, IL-4, IL-
13, and TGF-h. Initially, we wanted to explore the average
response of cytokine synthesis, by stimulating PBMC with
PMA plus ionomycin, as detailed in Materials and methods.
We observed that cytokine expression was similar for all
classes of subjects, in that all tested cytokines were
expressed (data not shown). Then, we analyzed the intra-
cellular cytokine production in the different subsets of T
cells (CD3+/CD4+ and CD3+/CD8+), in response to spe-
cific stimulation with HBsAg. We observed that T cells
from responders to hepatitis B vaccine produced significant
levels of all tested cytokines with no preferential profile
gy 326 (2004) 20–28 23
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those demonstrated in nonresponder subjects where intra-
cellular cytokine expression in response to HBsAg was
even lower than seen in naive individuals (P < 0.05). A
positive correlation between IL-2 production and SI was
observed (r = 0.58, P < 0.01). Additionally, a positive
correlation between IFN-g production and CD40L expres-
sion on T cells was verified (r = 0.6, P < 0.01).Discussion
The study of the response to hepatitis B vaccination
offers an interesting model to explore the complicated
molecular mechanisms that control the immune response
against purified proteins such as HBsAg. To date, the
underlying bases of human nonresponse to HBsAg areunknown. Development of a protective immune response
to this antigen is associated with the production of
specific neutralizing antibodies and, the process of anti-
body production to this glycoprotein antigen is T cell-
dependent and requires Th cell activation (Chisari and
Ferrari, 1995).
Several factors have been proposed to explain the ab-
sence of response to hepatitis B vaccine in about 5–10% of
immunized individuals and one of the most controversial,
regards the environment of secreted cytokines, which may
control the outcome of the immune response against
HBsAg. Analysis of in vitro HBsAg-induced cytokines
revealed: absence of Th1 cytokine production in nonre-
sponder subjects (Bocher et al., 1999; Chedid et al., 1997;
Vingerhoets et al., 1994), lack of Th2 response in both
responders and nonresponders (Vingerhoets et al., 1994),
absence of Th1 and Th2 cytokines in nonresponders (Kardar
L. Goncalves et al. / Virology 326 (2004) 20–28 25et al., 2002; Larsen et al., 2000), and production of both
cytokines in high responders (Larsen et al., 2000).
We decided to explore the T helper cell response in a
group of individuals classified as: nonimmunized healthy
controls, immunized nonresponder, and responder subjects
who had previously received a complete course of hepatitis
B vaccination. Our study involved: analysis of PBMC
specific proliferative response against HBsAg, intracellular
detection of specific cytokine production and detection of
HBsAg-induced activation and costimulatory molecules.
HBsAg-specific PBMC proliferation has been interpreted
as a positive indicator of in vitro effective immune response
(Vingerhoets et al., 1994). In our group of subjects, all
PBMC from nonresponders failed to proliferate in vitro
against HBsAg. Conversely, all PBMC from responders
with high anti-HBs titers developed a proliferative response
to HBsAg. These results confirmed previous observations
from several groups (Chedid et al., 1997; Larsen et al.,
2000; Vingerhoets et al., 1994).
As previously reported by Larsen et al. (2000), the in
vitro cytokine response to HBsAg is very complex and
subject-dependent. Both types of cytokine patterns, Th1 and
Th2 (IL-2/IFN-g and IL-4/IL-13, respectively) and addi-
tionally TGF-h were produced at significantly higher levels
in our responder subjects. In contrast, a diminished produc-
tion of all types of cytokines was observed in nonresponders
to hepatitis B vaccine and in naive subjects. A positive
correlation between IL-2 production and proliferation, as
well as between IL-4 synthesis and antibody titers, was
demonstrated in the entire group of individuals, which could
explain, in part, the detriment of both humoral and cellular
response against HBsAg. However, we must consider pre-
vious events that anticipate proliferation, cytokine and
antibody production, which may be involved in the nonre-
sponse phenomenon against HBsAg.
There are several factors that determine the fate of a
naive Th cell in response to antigenic challenge (Frauwirth
and Thompson, 2002; Kaech et al., 2002). These include
the strength of the TCR signal or antigen density, the
cytokine milieu, and specific costimulatory pathways.
Therefore, we explored the induction and expression of
two early activation markers (CD25 and CD69) and one of
the key ligands of costimulatory molecules named CD40L.
Purified HBsAg was unable to increase the expression of
both CD69 and CD25 in nonresponder subjects. Because
CD69 expression correlated with in vitro PBMC prolifer-
ation in response to HBsAg, these results suggest that lack
of proliferation could be a consequence of an inefficient
activation signal, either dependent on the antigen/APC axis
or secondarily to lack of commitment of the Th cell
lineage. To clarify this complex mechanism will require
intensive further studies. Our study also showed a dimin-
ished CD40L expression on Th cells in nonresponders,
following stimulation with HBsAg, in contrast to the high
levels observed for this molecule in responders to the
hepatitis B vaccination. A positive correlation betweenCD40L expression in CD4+ cells and specific IgG titers
was observed suggesting that the absence of humoral-
specific response to HBsAg, may be, in part, a result of
the inability of Th cells to induce switching of immuno-
globulins during maturation of B cell response. The
observed diminished specific in vitro induction of activa-
tion and costimulatory molecules represent new informa-
tion in our understanding of the immune response against
HBsAg. In conclusion, our results suggest an overall
inability of T cells to be activated which could be
consistent with potential differences in MHC/Ag presenta-
tion, therefore contributing to our understanding of the
altered T helper response as an underlying mechanism for
the absence of protective immunity against hepatitis B in a
minority of vaccinated individuals.Materials and methods
Subjects
Twenty-nine healthy volunteers, from 20 to 45 years old,
were recruited. From these group, twenty-one subjects had
previously received the standard hepatitis B vaccination
protocol (HBsAg recombinant; Engerix-B) and eight were
naive, nonimmunized controls. Individuals who had re-
ceived the full vaccination course more than 1 year earlier
received a single I.M. booster injection of Engerix-B vac-
cine (Smith Kline Blecham, Philadelphia). Nonresponder
individuals were defined as having very low or undetectable
serum anti-HBs titer, below 10 IU/l (n = 7) (Larsen et al.,
2000).
Blood samples for anti-HBsAg determination were
obtained from 5 to 7 weeks following the booster dose.
Anti-HBsAg, HBsAg, and anti-HBc were analyzed using
commercially available assays (Organon Teknike, Boxtel,
NL, USA).
Media and reagents
Complete media consisted of RPMI 1640 supplemented
with 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin, and
100 mg/ml streptomycin. All reagents were purchased from
GIBCO Life Technologies Inc, (Grand Island, NY, USA).
Lymphoprep was purchased from Nycomed Pharma (Oslo,
Norway). Phytohaemagglutinin (PHA), streptavidin, and
streptavidin-PE were purchased from Calbiochem (San
Diego, CA). Phytolacca americana lectin (PWM) was pur-
chased from Sigma (St. Louis, MO). Recombinant HBsAg
(rHBsAg; ayw subtype) was kindly provided by Hepatitis
Laboratory Branch Division of Viral Hepatitis, Center for
Disease Control and Prevention, Atlanta, GA, USA. Mouse
antihuman CD40L mAb PE-conjugated (clone TRAP1),
mouse antihuman IL-2 PE-conjugated (clone MQ1-
17H12), mouse antihuman IL-4 PE-conjugated (clone
MP4-25D2), mouse antihuman IL-13 PE-conjugated (clone
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4SB3), Citofix/Cytoperm, Golgi Plug were all purchased
from PharMingen (San Diego, CA). Biotinylated antihuman
TGF-h antibody was purchased from R&D Systems. Mouse
antihuman CD4 FITC-conjugated (clone Leu3a3b), mouse
antihuman CD8 FITC-conjugated (clone Leu3a), mouse
antihuman CD69 PE-conjugated (clone L78), isotype con-
trols, mouse IgG1 FITC-conjugated, PE and PerCp were
purchased from Becton & Dickinson, Co, (San Jose, CA,
USA). Mouse antihuman CD3 mAb PECy5-conjugated
(clone UCHT1) was purchased from Cytognos (Salamanca,
Spain). Mouse antihuman CD25 mAb PE-conjugated
(clone B1.49.9) was purchased from Immunotech Beckman
Coulter (Marseille, France).
PBMCs isolation
PBMCs were isolated from heparinized blood by density
gradient sedimentation over Lymphoprep. Freshly isolated
PBMCs (98% viable by trypan blue exclusion) were
resuspended in RPMI 1640 supplemented with 10% heat-
inactivated fetal bovine serum, 100 units/ml of penicillin,
and 0.1 mg/ml of streptomycin.
Antigen-specific PBMC stimulation and proliferation assays
PBMC (2  105/well) were plated in triplicate in round-
bottom 96-well plates with complete media with or without
(untreated control) 3 Ag/ml of PWM during 5 days or 5 Ag/
ml of purified recombinant HBsAg, during 7 days, at 37 jC
in a humidified atmosphere with 5% CO2. The same
antigen doses and stimulation conditions were used in the
rest of the assays. Eighteen hours before harvesting, 1 ACi/
well [3H]-thymidine was added to the culture per well
(Amersham International, Little Chalfont, UK). Cells were
collected onto glass fiber filters (Packard Instruments,
Groningen, The Netherlands) using an automated cell
harvester (Harvester 96 Mach III M Tomtec), and the
amount of radiolabel incorporated into DNA was measured
by a direct beta counter (Liquid Scintillation Analizer 1900
TR; Packard Instruments). Triplicates cultures were assayed
routinely and the results are expressed as mean counts per
minutes (cpm). The stimulation index (SI) was calculated as
the ratio between cpm obtained in the presence of antigen
and that obtained from the untreated control cultures.
Detection of CD69/CD25/CD40L molecules on T cells
A time course experiment was conducted to determinate
the optimal expression of activation surface markers. To
this purpose, purified PBMC were stimulated with HBsAg
during 24, 48, and 72 h. CD40L was optimally expressed
at 48 h incubation. CD25 and CD69 were detected up to
72 h of culture. Polyclonal stimulus was used in parallel to
explore the expression in all samples. For instance, to
induce CD40L expression, 200 ng/ml of PMA plus 500ng/ml of ionomycin during 6 h, were used. CD25 and
CD69 were induced by incubating the cells with 20 Ag/ml
of PHA during 18 h.
After incubation, cells were washed twice with cold PBS
and stained with the monoclonal antibodies of interest for 30
min at 4 jC. To identify a specific cell population, a double
staining using anti-CD3, anti-CD4, or anti-CD8 antibodies,
in combination with anti-CD40L, anti-CD25, or anti-CD69,
was performed. Following staining with the fluorochrome-
conjugated antibodies, cells were washed twice with cold
PBS–EDTA and fixed in a PBS solution containing 3%
paraformaldehyde for 10 min at room temperature. After
fixation, PBMC were analyzed by flow cytometry.
Flow cytometry analysis of surface markers
Phenotypic analysis of PBMC was performed on a fluo-
rescence-activated cell sorter (FACScan, Becton Dickinson
Immunocytometry system) using a set of fluorochrome-
labeled monoclonal antibodies against lymphocytes surface
markers. At the acquisition and analysis steps, the lympho-
cytes were selected in a gate by drawing a region around
the lymphocyte population on the forward scatter (FCS)/
side scatter (SSC) dot plot. Only the cells in this gate were
selected for further analysis (Mendes et al., 2000). Evalu-
ation of expression of surface markers was assessed by
looking at the relative number of positive cells and the
mean fluorescence intensity (MFI) estimated from the mean
channel numbers of CD69, CD25, and CD40L. Isotype
control antibodies were used to separate positive and
negative cells on FITC, PE, and PerCp fluorescence chan-
nels. A minimum of 10000 events were collected for each
analysis.
Induction and detection of intracellular cytokines by flow
cytometry
For intracellular cytokine detection at the single-cell
level, PBMC were incubated with media alone (unstimu-
latded), Phorbol myristate acetate (50 ng/ml), and iono-
mycin (1 Ag/ml) as a positive polyclonal stimulus for 4 h,
or 5 Ag of HBsAg, for a period of 96 h. To block cytokine
secretion at the Golgi, allowing for optimal detection of
the molecules, 1 Ag/ml of brefeldina A was added to the
culture simultaneously when cells were stimulated with
PMA plus ionomycin and 6 h before harvesting when
HBsAg was used as stimulus.
Cytokine production by different lymphocyte subpopu-
lations was evaluated through intracellular staining by
using the Citofix/Cytoperm Plus kit (Pharmingen) accord-
ing to the manufacturer’s instructions. Briefly, following
stimulation, PBMC at a concentration of 7  105 cells/well
were harvested, and resuspended in staining buffer and
subsequently stained for the surface markers CD3, CD4, or
CD8 by using fluorochrome-conjugated monoclonal anti-
bodies for 30 min at 4 jC. Cells were washed twice with
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solution for 20 min at 4 jC and washed twice with 1
perm/wash solution, which must be maintained in the
washing steps to keep cells permeable. Surface-stained,
fixed, and permeabilized cells were incubated with the anti-
cytokine antibody of interest. For IL-2, IL-4, IL-13, IFN-g
staining, cells were incubated for 30 min at 4jC in the
dark. After labeling, cells were washed twice with perm/
wash solution and finally resuspended in staining buffer
before flow cytometry analysis. For TGF-h staining, cells
were labeled for surface marker fixed and permeabilized
and incubated with a solution containing PBS/BSA 1% and
10 Ag/ml of streptavidin to block endogenous biotin. After
four washes with perm/wash solution, cells were incubated
with a monoclonal biotinylated anti-TGF-h antibody for 30
min at 4 jC, washed twice with perm/wash solution, and
incubated with streptavidin-PE for 30 min at 4 jC in the
dark. After the appropriate washing steps, cells were
resuspended in staining buffer and prepared for flow
cytometry analysis.
Statistical analysis
Results from the proliferation assays were presented as
means from triplicates F SD. Differences in mean values of
surface markers and cytokines expression between the
different groups of subjects were calculated using the
student t test. All described correlations were analyzed by
linear regression.Acknowledgments
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